Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-b/RUNX axis

Science Advances

Volumn 1, Issue 8, 2015, Pages

  Anderson, Brett D ^a   Harris, Reuben S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DEGRADATION; DISEASES; GENE EXPRESSION; GENES; LYMPHOCYTES; NUCLEIC ACIDS; T-CELLS; VIRUSES;

COMPLEMENTATION; CYTOSINE DEAMINASES; DNA REPLICATIONS; MEDIATED TRANSCRIPTION; PROTEASOMAL DEGRADATION; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL REGULATION; VIRAL INFECTIONS;

TRANSCRIPTION;

EID: 84976447075     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1500296     Document Type: Article

References (39)

1. B. Beutler, C. Eidenschenk, K. Crozat, J.-L. Imler, O. Takeuchi, J. A. Hoffmann, S. Akira, Genetic analysis of resistance to viral infection. Nat. Rev. Immunol. 7, 753–766 (2007).
2. M. H. Malim, P. D. Bieniasz, HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2, a006940 (2012).
3. B. A. Desimmie, K. A. Delviks-Frankenberrry, R. C. Burdick, D. Qi, T. Izumi, V. K. Pathak, Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 426, 1220–1245 (2014).
4. E. W. Refsland, R. S. Harris, The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 371, 1–27 (2013).
5. K. Strebel, HIV accessory proteins versus host restriction factors. Curr. Opin. Virol. 3, 692–699 (2013).
6. E. W. Refsland, J. F. Hultquist, R. S. Harris, Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLOS Pathog. 8, e1002800 (2012).
7. M. Ooms, B. Brayton, M. Letko, S. M. Maio, C. D. Pilcher, F. M. Hecht, J. D. Barbour, V. Simon, HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 14, 411–421 (2013).
8. E. W. Refsland, J. F. Hultquist, E. M. Luengas, T. Ikeda, N. M. Shaban, E. K. Law, W. L. Brown, C. Reilly, M. Emerman, R. S. Harris, Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLOS Genet. 10, e1004761 (2014).
9. K. Sato, T. Izumi, N. Misawa, T. Kobayashi, Y. Yamashita, M. Ohmichi, M. Ito, A. Takaori-Kondo, Y. Koyanagi, Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J. Virol. 84, 9546–9556 (2010).
10. S. Jäger, D. Y. Kim, J. F. Hultquist, K. Shindo, R. S. LaRue, E. Kwon, M. Li, B. D. Anderson, L. Yen, D. Stanley, C. Mahon, J. Kane, K. Franks-Skiba, P. Cimermancic, A. Burlingame, A. Sali, C. S. Craik, R. S. Harris, J. D. Gross, N. J. Krogan, Vif hijacks CBF-b to degrade APOBEC3G and promote HIV-1 infection. Nature 481, 371–375 (2011).
11. W. Zhang, J. Du, S. L. Evans, Y. Yu, X.-F. Yu, T-cell differentiation factor CBF-b regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376–379 (2011).
12. J. F. Hultquist, M. Binka, R. S. LaRue, V. Simon, R. S. Harris, Vif proteins of human and simian immunodeficiency viruses require cellular CBFb to degrade APOBEC3 restriction factors. J. Virol. 86, 2874–2877 (2012).
13. W. Zhang, H. Wang, Z. Li, X. Liu, G. Liu, R. S. Harris, X. F. Yu, Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins. J. Virol. 88, 12528–12540 (2014).
14. X. Han, W. Liang, D. Hua, X. Zhou, J. Du, S. L. Evans, Q. Gao, H. Wang, R. Viqueira, W. Wei, W. Zhang, X.-F. Yu, Evolutionarily conserved requirement for core binding factor beta in the assembly of the human immunodeficiency virus/simian immunodeficiency virus Vif-cullin 5-RING E3 ubiquitin ligase. J. Virol. 88, 3320–3328 (2014).
15. Y. Ai, D. Zhu, C. Wang, C. Su, J. Ma, J. Ma, X. Wang, Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation. J. Virol. 88, 12112–12122 (2014).
16. J. Zhang, J. Wu, W. Wang, H. Wu, B. Yu, J. Wang, M. Lv, X. Wang, H. Zhang, W. Kong, X. Yu, Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins. Retrovirology 11, 77 (2014).
17. Y. Guo, L. Dong, X. Qiu, Y. Wang, B. Zhang, H. Liu, Y. Yu, Y. Zang, M. Yang, Z. Huang, Structural basis for hijacking CBF-b and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505, 229–233 (2014).
18. W. F. Wong, K. Kohu, T. Chiba, T. Sato, M. Satake, Interplay of transcription factors in T-cell differentiation and function: The role of Runx. Immunology 132, 157–164 (2011).
19. Y. Ito, Oncogenic potential of the RUNX gene family: ‘Overview’. Oncogene 23, 4198–4208 (2004).
20. D. Y. Kim, E. Kwon, P. D. Hartley, D. C. Crosby, S. Mann, N. J. Krogan, J. D. Gross, CBFb stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49, 632–644 (2013).
21. J. F. Hultquist, R. M. McDougle, B. D. Anderson, R. Harris, HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor b on genetically distinct surfaces. AIDS Res. Hum. Retroviruses 28, 1543–1551 (2012).
22. P. D. Hsu, E. S. Lander, F. Zhang, Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).
23. T. Nagata, M. H. Werner, Functional mutagenesis of AML1/RUNX1 and PEBP2b/CBFb define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain. J. Mol. Biol. 308, 191–203 (2001).
24. E. W. Refsland, M. D. Stenglein, K. Shindo, J. S. Albin, W. L. Brown, R. S. Harris, Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: Implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274–4284 (2010).
25. F. A. Koning, E. N. Newman, E.-Y. Kim, K. J. Kunstman, S. M. Wolinsky, M. H. Malim, Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83, 9474–9485 (2009).
26. B. K. Thielen, J. P. McNevin, M. J. McElrath, B. V. Hunt, K. C. Klein, J. R. Lingappa, Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J. Biol. Chem. 285, 27753–27766 (2010).
27. M. D. Stenglein, M. B. Burns, M. Li, J. Lengyel, R. S. Harris, APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17, 222–229 (2010).
28. M. Bonvin, F. Achermann, I. Greeve, D. Stroka, A. Keogh, D. Inderbitzin, D. Candinas, P. Sommer, S. Wain-Hobson, J. P. Vartanian, J. Greeve, Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364–1374 (2006).
29. Y. Tanaka, H. Marusawa, H. Seno, Y. Matsumoto, Y. Ueda, Y. Kodama, Y. Endo, J. Yamauchi, T. Matsumoto, A. Takaori-Kondo, I. Ikai, T. Chiba, Anti-viral protein APOBEC3G is induced by interferon-a stimulation in human hepatocytes. Biochem. Biophys. Res. Commun. 341, 314–319 (2006).
30. M. A. Farrow, E.-Y. Kim, S. M. Wolinsky, A. M. Sheehy, NFAT and IRF proteins regulate transcription of the anti-HIV gene, APOBEC3G. J. Biol. Chem. 286, 2567–2577 (2011).
31. M. B. Burns, L. Lackey, M. A. Carpenter, A. Rathore, A. M. Land, B. Leonard, E. W. Refsland, D. Kotandeniya, N. Tretyakova, J. B. Nikas, D. Yee, N. A. Temiz, D. E. Donohue, R. M. McDougle, W. L. Brown, E. K. Law, R. S. Harris, APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366–370 (2013).
32. M. B. Burns, N. A. Temiz, R. S. Harris, Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977–983 (2013).
33. B. Leonard, S. N. Hart, M. B. Burns, M. A. Carpenter, N. A. Temiz, A. Rathore, R. I. Vogel, J. B. Nikas, E. K. Law, W. L. Brown, Y. Li, Y. Zhang, M. J. Maurer, A. L. Oberg, J. M. Cunningham, V. Shridhar, D. A. Bell, C. April, D. Bentley, M. Bibikova, R. K. Cheetham, J.-B. Fan, R. Grocock, S. Humphray, Z. Kingsbury, J. Peden, J. Chien, E. M. Swisher, L. C. Hartmann, K. R. Kalli, E. L. Goode, H. Sicotte, S. H. Kaufmann, R. S. Harris, APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73, 7222–7231 (2013).
34. C. J. Warren, T. Xu, K. Guo, L. M. Griffin, J. A. Westrich, D. Lee, P. F. Lambert, M. L. Santiago, D. Pyeon, APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89, 688–702 (2015).
35. V. C. Vieira, B. Leonard, E. A. White, G. J. Starrett, N. A. Temiz, L. D. Lorenz, D. Lee, M. A. Soares, P. F. Lambert, P. M. Howley, R. S. Harris, Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 5, e02234-14 (2014).
36. R. S. LaRue, S. R. Jónsson, K. A. T. Silverstein, M. Lajoie, D. Bertrand, N. El-Mabrouk, I. Hötzel, V. Andrésdóttir, T. P. L. Smith, R. S. Harris, The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9, 104 (2008).
37. N. E. Sanjana, O. Shalem, F. Zhang, Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
38. J. F. Hultquist, J. A. Lengyel, E. W. Refsland, R. S. LaRue, L. Lackey, W. L. Brown, R. S. Harris, Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220–11234 (2011).
39. ENCODE Project Consortium, An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).